Skip to main content
Top
Published in: Breast Cancer Research 2/2008

01-05-2008 | Poster presentation

The QUEST study: a multicentre randomised trial to assess the impact of the type and timing of breast reconstruction on quality of life following mastectomy

Authors: S Potter, ZE Winters

Published in: Breast Cancer Research | Special Issue 2/2008

Login to get access

Excerpt

Breast reconstruction is performed to improve the quality of life and body image for women facing mastectomy. Whilst significant anecdotal evidence and surgical dogma exists regarding the optimal reconstructive practice, a comprehensive MEDLINE literature review has revealed a paucity of well designed, statistically powered studies to address the impact of either the type or the timing of breast reconstruction on these key patient-reported outcomes. There is little high-quality evidence to support the benefit of immediate versus delayed breast reconstruction, for example, or to suggest the superiority of autologous over implant-assisted reconstructions in terms of improvements in quality of life or body image, particularly in the context of postoperative radiotherapy (RT). There is also very limited evaluation of the impact of latissimus dorsi (LD) breast reconstruction, although this is the procedure most commonly offered by oncoplastic breast surgeons in the UK. There is currently, therefore, very little to guide patients or their surgeons in making important decisions regarding their reconstructive options. …
Metadata
Title
The QUEST study: a multicentre randomised trial to assess the impact of the type and timing of breast reconstruction on quality of life following mastectomy
Authors
S Potter
ZE Winters
Publication date
01-05-2008
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2008
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1971

Other articles of this Special Issue 2/2008

Breast Cancer Research 2/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine